



October 21, 2020

PRESS RELEASE

Company: RaQualia Pharma Inc.

(Ticker code: 4579)

Representative: Representative Director Naoki Tani

Inquiries: Director Kiichiro Kawada

(Phone +81-52-446-6100)

FDA Approves ELURA® (capromorelin oral solution) for Managing Weight Loss in Cats with Chronic Kidney Disease

October 19, 2020---The U.S. Food and Drug Administration has approved ELURA® (capromorelin oral solution), the second drug approved for management of weight loss in cats and the first drug approved specifically for the management of weight loss in cats with chronic kidney disease.

Please see the "CVM update" announcement on the U.S. FDA's website

<https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-elura-capromorelin-oral-solution-managing-weight-loss-cats-chronic-kidney-disease>

In December 2010, RaQualia Pharma Inc. (RaQualia) entered into a licensing agreement with Aratana Therapeutics Inc. (currently Elanco Animal Health Inc.) regarding the worldwide commercialization of its ELURA® (capromorelin oral solution) as veterinary drugs. RaQualia is eligible to receive a fixed rate of royalty on the sales of the product.

End